NCT00334776View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

MART-1 antigen

BIOLOGICAL

gp100:209-217(210M) peptide vaccine

BIOLOGICAL

therapeutic autologous dendritic cells

BIOLOGICAL

tyrosinase peptide

Trial Locations (2)

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

48109-0942

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT00334776 - Vaccine Therapy in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter